Literature DB >> 30279003

Refining Early Antitumoral Drug Development.

Alberto Ocaña1, Sara García-Alonso2, Eitan Amir3, Atanasio Pandiella4.   

Abstract

The failure rate of development of new drugs in oncology is high, with up to 95% of drugs tested in Phase I not reaching the market. Causes behind this high failure rate are discussed here, and solutions to increase the success in the development of antitumor drugs are suggested.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Keywords:  drug development; oncology

Mesh：

Substances：

Year:  2018        PMID： 30279003     DOI： 10.1016/j.tips.2018.09.003

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  8 in total

Review 1.  Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis.

Authors:  Alexandra Desnoyers; Carlos González; Pedro Pérez-Segura; Atanasio Pandiella; Eitan Amir; Alberto Ocaña
Journal:  Mol Diagn Ther       Date:  2020-04       Impact factor: 4.074

2.  Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.

Authors:  María Del Mar Noblejas-López; Cristina Nieto-Jimenez; Miguel Burgos; Mónica Gómez-Juárez; Juan Carlos Montero; Azucena Esparís-Ogando; Atanasio Pandiella; Eva M Galán-Moya; Alberto Ocaña
Journal:  J Exp Clin Cancer Res       Date:  2019-08-30

3.  Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.

Authors:  Cristina Nieto-Jimenez; Ana Alcaraz-Sanabria; Sandra Martinez-Canales; Veronica Corrales-Sanchez; Juan Carlos Montero; Miguel Burgos; Miriam Nuncia-Cantarero; Atanasio Pandiella; Eva M Galan-Moya; Alberto Ocaña
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

4.  Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates.

Authors:  Ana Alcaraz-Sanabria; Esther Cabañas Morafraile; Gonzalo Fernández-Hinojal; Guillermo Velasco; Pedro Pérez-Segura; Atanasio Pandiella; Balázs Győrffy; Alberto Ocaña
Journal:  Front Immunol       Date:  2022-02-01       Impact factor: 7.561

Review 5.  Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?

Authors:  Ludovica Lospinoso Severini; Francesca Bufalieri; Paola Infante; Lucia Di Marcotullio
Journal:  Front Cell Dev Biol       Date:  2022-02-15

Review 6.  Clinical considerations for the design of PROTACs in cancer.

Authors:  Cristina Nieto-Jiménez; Esther Cabañas Morafraile; Carlos Alonso-Moreno; Alberto Ocaña
Journal:  Mol Cancer       Date:  2022-03-07       Impact factor: 27.401

7.  Plocabulin Displays Strong Cytotoxic Activity in a Personalized Colon Cancer Patient-Derived 3D Organoid Assay.

Authors:  Alba Costales-Carrera; Asunción Fernández-Barral; Pilar Bustamante-Madrid; Laura Guerra; Ramón Cantero; Antonio Barbáchano; Alberto Muñoz
Journal:  Mar Drugs       Date:  2019-11-19       Impact factor: 5.118

Review 8.  Proteolysis targeting chimeras (PROTACs) in cancer therapy.

Authors:  Alberto Ocaña; Atanasio Pandiella
Journal:  J Exp Clin Cancer Res       Date:  2020-09-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.